MedTrace Logo

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

NCT06798376 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-01-29

No results posted yet for this study

Summary

The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are:

* Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)?
* How does treatment duration affect perioperative safety and clinical outcomes?

Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.

Conditions

  • Gastric Adenocarcinoma

Interventions

DRUG

≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy

Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles

DRUG

≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy

Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles

PROCEDURE

Gastrectomy

Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06798376 on ClinicalTrials.gov